Cancer Vaccines and Immunotherapy

Cancer Vaccines and Immunotherapy PDF Author: Peter L. Stern
Publisher: Cambridge University Press
ISBN: 9780521622639
Category : Medical
Languages : en
Pages : 304

Get Book Here

Book Description
Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments.

Cancer Vaccines and Immunotherapy

Cancer Vaccines and Immunotherapy PDF Author: Peter L. Stern
Publisher: Cambridge University Press
ISBN: 9780521622639
Category : Medical
Languages : en
Pages : 304

Get Book Here

Book Description
Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments.

Immunization Safety Review

Immunization Safety Review PDF Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309086108
Category : Medical
Languages : en
Pages : 118

Get Book Here

Book Description
The Immunization Safety Review Committee was established by the Institute of Medicine (IOM) to evaluate the evidence on possible causal associations between immunizations and certain adverse outcomes, and to then present conclusions and recommendations. The committee's mandate also includes assessing the broader societal significance of these immunization safety issues. While all the committee members share the view that immunization is generally beneficial, none of them has a vested interest in the specific immunization safety issues that come before the group. The committee reviews three immunization safety review topics each year, addressing each one at a time. In this fifth report in a series, the committee examines the hypothesis that exposure to polio vaccine contaminated with simian virus 40 (SV40), a virus that causes inapparent infection in some monkeys, can cause certain types of cancer.

Vaccines for Cancer Immunotherapy

Vaccines for Cancer Immunotherapy PDF Author: Nima Rezaei
Publisher: Academic Press
ISBN: 0128140402
Category : Science
Languages : en
Pages : 200

Get Book Here

Book Description
Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians, scientists, and researchers working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines. Vaccines for Cancer Immunotherapy provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines. - Introduces the feasible immunotherapeutic vaccines for patients with different types of cancer - Presents the status of past and current vaccines for cancer treatment - Considers advantages and disadvantages of different therapeutic cancer vaccines - Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods - Analyzes obstacles to development of therapeutic cancer vaccines - Gives a view on future perspectives in the application of therapeutic cancer vaccines

Cancer Vaccination and Challenges

Cancer Vaccination and Challenges PDF Author: Rishabha Malviya
Publisher: CRC Press
ISBN: 1040100481
Category : Technology & Engineering
Languages : en
Pages : 389

Get Book Here

Book Description
Volume 1: Strategies for Therapeutic Cancer Vaccine Development deals with strategies of cancer vaccine development, focussing on the techniques for the development of therapeutic cancer vaccines and the role of tumor antigens, proteins/peptides, microbial genes, and stem cells for the development of vaccines for cancer management. . Volume 2: Delivery Strategies for Cancer Vaccine and Immunotherapy in Management of Various Carcinomas covers delivery strategies of cancer vaccines for the management of various forms of carcinoma, examining the prospects of delivering immuno-oncology therapies, focusing specifically on effective drug delivery strategies for the treatment of lung, prostate, and pancreatic carcinomas.

The Ethics of Vaccination

The Ethics of Vaccination PDF Author: Alberto Giubilini
Publisher: Springer
ISBN: 3030020681
Category : Philosophy
Languages : en
Pages : 137

Get Book Here

Book Description
This open access book discusses individual, collective, and institutional responsibilities with regard to vaccination from the perspective of philosophy and public health ethics. It addresses the issue of what it means for a collective to be morally responsible for the realisation of herd immunity and what the implications of collective responsibility are for individual and institutional responsibilities. The first chapter introduces some key concepts in the vaccination debate, such as ‘herd immunity’, ‘public goods’, and ‘vaccine refusal’; and explains why failure to vaccinate raises certain ethical issues. The second chapter analyses, from a philosophical perspective, the relationship between individual, collective, and institutional responsibilities with regard to the realisation of herd immunity. The third chapter is about the principle of least restrictive alternative in public health ethics and its implications for vaccination policies. Finally, the fourth chapter presents an ethical argument for unqualified compulsory vaccination, i.e. for compulsory vaccination that does not allow for any conscientious objection. The book will appeal to philosophers interested in public health ethics and the general public interested in the philosophical underpinning of different arguments about our moral obligations with regard to vaccination.

Vaccinophobia and Vaccine Controversies of the 21st Century

Vaccinophobia and Vaccine Controversies of the 21st Century PDF Author: Archana Chatterjee
Publisher: Springer Science & Business Media
ISBN: 1461474388
Category : Medical
Languages : en
Pages : 503

Get Book Here

Book Description
Vaccinophobia and Vaccine Controversies of the 21st Century Archana Chatterjee, editor Once hailed as a medical miracle, vaccination has come under attack from multiple fronts, including occasionally from within medicine. And while the rates of adverse reactions remain low, suggestions that vaccines can cause serious illness (and even death) are inspiring parents to refuse routine immunizations for their children--ironically, exposing them and others to potentially serious illness. Vaccinophobia and Vaccine Controversies of the 21st Century explains clearly how this state of affairs came into being, why it persists, and how healthcare professionals can best respond. Current findings review answers to bedrock questions about known adverse events, what vaccine additives are used for, and real and perceived risks involved in immunization. Perspectives representing pediatricians, family practitioners, nurses, parents, pharmacy professionals, the CDC, and the public health community help the reader sort out legitimate from irrational concerns. In-depth analyses discuss the possibility of links with asthma, cancer, Guillain-Barre syndrome, SIDS, and, of course, autism. Included in the coverage: Communicating vaccine risks and benefits The vaccine misinformation landscape in family medicine Perceived risks from live viral vaccines The media's role in vaccine misinformation Autoimmunity, allergies, asthma, and a relationship to vaccines Vaccines and autism: the controversy that won't go away The conundrums described here are pertinent to practitioners in pediatrics, family medicine, primary care, and nursing to help families with informed decision making. In addition, Vaccinophobia and Vaccine Controversies of the 21st Century should be read by trainees and researchers in child development and maternal and child health as the book's issues will have an impact on future generations of children and their families.

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment PDF Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 030944232X
Category : Medical
Languages : en
Pages : 135

Get Book Here

Book Description
Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.

Lipid A in Cancer Therapy

Lipid A in Cancer Therapy PDF Author: Jean-Francois Jeannin
Publisher: Springer Science & Business Media
ISBN: 1441916032
Category : Medical
Languages : en
Pages : 145

Get Book Here

Book Description
Cancer remains a major challenge for modern society. Not only does cancer rank among the first three causes of mortality in most population groups but also the therapeutic options available for most tumor types are limited. The existing ones have limited efficacy, lack specificity and their administration carry major side effects. Hence the urgent need for novel cancer therapies. One of the most promising avenues in research is the use of specific immunotherapy. The notion that the immune system may have important anti-tumor effects has been around for more than a century now. Every major progress in microbiology and immunology has been immediately followed by attempts to apply the new knowledge to the treatment of cancer. Progress has reached a point where it is well established that most cancer patients mount specific T cell responses against their tumors. The molecular identity of the antigens recognized by anti-tumor T cells has been elucidated and several hundreds of tumor-derived antigenic peptides have been discovered. Upon recognition of such peptides presented by self MHC molecules, both CD8 and CD4 T cells are activated, expand to high numbers and differentiate into effective anti-tumor agents. CD8 T cells directly destroy tumor cells and can cause even large tumors to completely regress in experimental mouse models. These observations have spurred intense research activity aimed at designing and testing cancer vaccines. Over 100 years ago Coley successfully used intratumoral injection of killed bacteria to treat sarcomas. The important anti-tumor effects observed in a fraction of these patients fueled major research efforts. These led to major discoveries in the 80s and the 90s. It turns out that bacterial lipopolysaccharides stimulate the production of massive amounts of a cytokine still known today as tumor necrosis factor (TNF-a). They do so by engagement of a rather complex set of interactions culminating in the ligation of a Toll-like receptor, TLR -4. Ensuing signaling through this receptor initiates potent innate immune responses. Unfortunately the clinical use of both TNF-a and LPS can not be generalized due to their very narrow therapeutic margin. Importantly, synthetic Lipid A analogs have been identified that retain useful bioactivity and yet possess only mild toxicity. The relatively large body of information accumulated thus far on the molecular and cellular interactions set in motion by administration of LPS as well as by the synthetic lipid A analogs allow to place this family of bacterially-derived molecules at the crossroads between innate and adaptive immunity. By virtue of this key position, the therapeutic applications being pursued aim at using these compounds either as direct anti-tumor agents or as vaccine adjuvants. The clinical experience acquired so far on these two avenues is asymmetric. Few clinical trials using Lipid A analogs as single anti-cancer agents involving less than 100 patients with advanced cancer have been reported. In contrast, lipid A has been tested in over 300,000 individuals in various vaccines trials, including therapeutic cancer vaccines. Clearly most of the work needed to develop lipid A as effective anti-cancer agents and/or as vaccine adjuvant lies ahead in the near future. This book is a timely contribution and provides a much needed up-to-date overview of the chemical, biological and physiological aspects of lipid A. It should be a beacon to all those involved in this field of research.

Opportunities in Biotechnology for Future Army Applications

Opportunities in Biotechnology for Future Army Applications PDF Author: National Research Council
Publisher: National Academies Press
ISBN: 0309075556
Category : Science
Languages : en
Pages : 118

Get Book Here

Book Description
This report surveys opportunities for future Army applications in biotechnology, including sensors, electronics and computers, materials, logistics, and medical therapeutics, by matching commercial trends and developments with enduring Army requirements. Several biotechnology areas are identified as important for the Army to exploit, either by direct funding of research or by indirect influence of commercial sources, to achieve significant gains in combat effectiveness before 2025.

Vaccines for the 21st Century

Vaccines for the 21st Century PDF Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309174988
Category : Medical
Languages : en
Pages : 472

Get Book Here

Book Description
Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis. What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development. This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines: Lessons to be learned from the polio experience. Scientific advances that set the stage for new vaccines. Factors that affect how vaccines are used in the population. Value judgments and ethical questions raised by comparison of health needs and benefits. The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.